Ryan Allway
May 5th, 2021
Vancouver, BC – May 5, 2021 – Entheon Biomedical Corp. (CSE: “ENBI”; OTCQB: “ENTBF”; FSE: “1XU1”) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market (“OTCQB”) effective May 5, 2021.
“We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availability of our subsidiary, HaluGen Life Science’s Psychedelics Genetic Test, we are pleased to be gaining increased visibility and investor access within the U.S. market,” said Timothy Ko, CEO of Entheon.
The shares will trade on the OTCQB under trading symbol “ENTBF”. The Company’s shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “ENBI” as well as the Frankfurt Stock Exchange (FSE) under the symbol “1XU1”.
This U.S. listing will provide the Company with access to a broader base of U.S. and international retail and institutional investors, ultimately providing investors with increased access to data, transparency and liquidity.
Investors can find real-time quotes and market information for the Company on https://www.otcmarkets.com.
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
On Behalf of the Board of Directors:
Timothy Ko, CEO
For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
[email protected]
https://www.entheonbiomedical.com
For media inquiries, please contact Crystal Quast at:
Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
[email protected]
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers